Back to mobile site

Survey finds Alzheimer's agitation often goes unrecognized until daily disruption

September 21, 2026 7:02 AM EDT

Axsome Therapeutics (NASDAQ: AXSM) released results from a caregiver survey on Alzheimer's disease agitation, presented at Psych Congress 2026 in New Orleans on September 17 and 18, 2026, coinciding with World Alzheimer's Day.

The Shared Goals: Navigating Alzheimer's Agitation survey, conducted online by The Harris Poll in collaboration with CaringKind and sponsored by Axsome, polled 751 adults in the U.S. who provide unpaid care to a loved one with Alzheimer's disease. The survey was conducted between October 7 and 28, 2025.

According to the survey, 97% of care partners reported that agitation negatively affected their loved one's quality of life, while 96% said it impaired the patient's ability to care for themselves. Three in four care partners said they wished they had recognized agitation symptoms sooner, and 53% reported regretting not consulting a healthcare provider earlier.

The survey identified nonaggressive symptoms, including complaining, negativism, and frequent unwarranted requests for help, as among the most detrimental to a patient's quality of life, cited by 76% of respondents. Repetitive sentences or questions were cited by 75%, repetitive mannerisms by 67%, and pacing or aimless wandering by 56%.

Care partners also reported unmet needs in managing the condition. Nearly half, 47%, said they were uncertain about medication decisions, and 93% expressed a desire for a medication that reduced agitation symptoms without additional side effects. Additionally, 89% wished for an easier way to track symptoms over time, and 81% wanted a method to share symptom information discreetly with their loved one's doctor.

"Recognizing these behaviors early and discussing them with a healthcare provider allows families and clinicians to set shared goals for care and discuss treatment options," said Brent P. Forester, M.D., psychiatrist-in-chief at Tufts Medical Center.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Related Entities

Maynard Um, Mark Zuckerberg, FDA, ARK